At EBiSC, we need no persuading that iPSCs are transforming how we study neurodegenerative diseases, offering scalable, human-relevant systems for understanding disease biology. Among the most impactful innovations are inducible, gene-edited models that allow precise temporal and spatial control of disease-associated proteins. EBiSC provides a suite of such tools focused on α-synuclein (SNCA)—a central player in Parkinson’s disease.
Flexible SNCA Modelling with Inducible iPSC Lines
The EBiSC lines BIONi010-C-43, BIONi010-C-44, BIONi010-C-49 and BIONi010-C-50 are designed to enable investigation into α-synuclein biology with high precision. All four feature doxycycline-inducible SNCA expression inserted into the AAVS1 locus, enabling controlled, dose-dependent induction.
Ubiquitous Expression Models: BIONi010-C-43 and BIONi010-C-44
- SNCA expression is driven by the CAG promoter (broad expression across cell types)
- BIONi010-C-43 encodes wild-type SNCA: https://ebisc.org/BIONi010-C-43
- BIONi010-C-44 encodes the A53T pathogenic mutation: https://ebisc.org/BIONi010-C-44
- Both iPSC lines include HA-tagged constructs to distinguish exogenous from endogenous α-synuclein
Neuron-Specific Expression Models: BIONi010-C-49 and BIONi010-C-50
- SNCA expression is controlled via the Synapsin-1 (hSyn) promoter
- This restricts expression to neuronal cells
- Both lines use neuron-specific M2rtTA for doxycycline inducibility
- BIONi010-C-49 encodes wild-type SNCA: https://ebisc.org/BIONi010-C-49
- BIONi010-C-50 encodes the A53T pathogenic mutation: https://ebisc.org/BIONi010-C-50
Spotlight on BIONi010-C-24: A Translational Model
BIONi010-C-24 (https://ebisc.org/BIONi010-C-24) is a gene-edited human iPSC line featuring doxycycline-inducible expression of A53T α-synuclein, a mutation strongly linked to familial Parkinson’s disease. This system allows precise control over disease-relevant protein expression, supporting reproducible and scalable experimental workflows.
In the publication “Establishment of a human induced pluripotent stem cell neuronal model for identification of modulators of A53T α-synuclein levels and aggregation” (PMID: 34932569), EBiSC project partners Bioneer and Lundbeck demonstrate the potential of this line.
Key highlights from the study include:
- Differentiation into functional cortical neurons with spontaneous activity
- Robust expression of neuronal markers
- Controlled induction and quantification of α-synuclein aggregation, a hallmark of Parkinson’s pathology
Importantly, the model proved suitable for drug discovery and target validation, with compatibility for scalable production and genetic screening approaches, including siRNA-based modulation. Notably, findings from this human neuronal system demonstrated differences coma[pred to non-human and immortalised models—emphasising the importance of physiologically relevant platforms in translational research.